Shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) fell 4.6% during mid-day trading on Monday . The stock traded as low as $1.94 and last traded at $1.99. 4,756 shares were traded during mid-day trading, a decline of 99% from the average session volume of 842,200 shares. The stock had previously closed at $2.08.
Ampliphi Biosciences Stock Performance
Ampliphi Biosciences Company Profile
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.
Read More
- Five stocks we like better than Ampliphi Biosciences
- Investing In Automotive Stocks
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What is the Australian Securities Exchange (ASX)
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- 3 Best Fintech Stocks for a Portfolio Boost
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
